Morphocell Technologies

Proud to support the Stem Cell Network for the #TMM2024. Meet our team during the conference, come see us at Morphocell Technologies booth and don’t miss our session on Tissue-engineered products on Nov 5 at lunchtime

🚨 Exciting News from Morphocell Technologies! 🚨 We are thrilled to welcome Dr. Paul K. Wotton to Morphocell Technologies’ Board of Directors! Dr. Wotton brings over 30 years of experience in biotechnology and cell therapy, with a remarkable background in strategic growth and high-profile transactions that have transformed multiple biotech companies. As a seasoned leader, Dr. Wotton has been instrumental in groundbreaking advancements and prominent partnerships across the industry. His expertise and vision align seamlessly with our commitment to pioneering transformative therapies for liver disease and organ replacement. Massimiliano Paganelli, CEO of Morphocell Technologies, shared, “Paul’s addition to our board strengthens our mission to bring cutting-edge treatments to patients in critical need. His depth in cell therapies and strategic leadership will drive Morphocell’s next phase of growth.” Learn more on Dr. Wotton here: https://lnkd.in/eEjpywyF Join us in welcoming Dr. Wotton to the Morphocell team as we continue our journey to make advanced therapeutic solutions accessible to patients worldwide! #Biotechnology #TissueEngineering #CellTherapy #RegenerativeMedicine #HealthcareInnovation #BoardAnnouncement

Join us at #TMM2024 for an exciting session tackling engineered tissues in #RegenerativeMedicine and the challenges of bringing to market these revolutionary products at the cutting edge of science and technology. "Tissue-Engineered Products: Challenges Beyond Cell Therapies" with Claudia Raggi, Tejal Desai, Patrick Bedford, Yohannes Haile, and Panos C.. #AdvancedTherapies

🔬Hier débutait notre tournée dans le cadre de #BioJapan2024 avec nos 13 entreprises et organisations québécoises, fières représentantes de notre écosystème des #sciencesdelavie. Pour cette première journée, nous étions à #Osaka, un hub des sciences de la vie au Japon afin d’y rencontrer les grands joueurs de la région et mettre de l’avant nos technologies. 🏯Avec l’Expo universelle d’Osaka qui approche, la ville est devenue un passage obligé et offre un environnement propice à l’innovation avec des infrastructures de pointe et des soutiens gouvernementaux attractifs. Merci à nos nombreux partenaires dans la région qui rendent possible cet événement au bénéfice de nos deux écosystèmes respectifs des sciences de la vie. 🚅Nous serons à #Yokohama dès mercredi, passez-nous voir au kiosque B-067! Ananda Devices Biodextris BIOQuebec Biotech City Ebovir Biotechnologie Inc Immugenia Inc. Mila - Quebec Artificial Intelligence Institute Montréal International Morphocell Technologies NeuroServo Novatek International Pytri Zilia Invest Quebec | Investissement Québec International Cynthia Delisle, CPA, CA ● Joanie Leroux-Côté Stephane Fallecker Délégation générale du Québec à Tokyo (DGQT) Emi KOKADO

We are thrilled to announce that Dr. Vincent Ling has joined Morphocell Technologies as our new Chief Business Officer! 🎉 Vincent brings an impressive 30 years of experience in biotech and pharma innovation. Based in Boston and Cambridge, he spent 12 years at Takeda Pharmaceuticals, where he led efforts to identify, finance, and develop early-stage pipelines across therapeutic areas and billion-dollar franchises. Vincent has an extremely rare business expertise at the crossroad of cell therapy, biologics, genetic engineering, advanced biomaterial and drug delivery, based on rock-solid scientific background. He is renowned for his pioneering work in the biotech field, including his support for the Kariko-Weissman mRNA vaccine technology from the University of Pennsylvania, which evolved into the first COVID-19 mRNA vaccine and led to the 2023 Nobel Prize in Physiology and Medicine. Vincent's unparalleled expertise and visionary leadership make him an invaluable addition to our executive team. His remarkable track record of pioneering advancements aligns perfectly with our mission at Morphocell. 🚀 We look forward to the exciting journey ahead with Vincent Ling on board! Read the full announcement here: https://lnkd.in/eMM6zHiK

📢 We are thrilled to announce the appointment of Marc Courtois to our Board of Directors! Marc brings over 20 years of extensive experience as an investment banker with RBC Capital Markets, where he managed major clients like Quebecor, BCE, and Air Canada. He played a pivotal role in complex processes such as the IPOs of Air Canada, Bell Canada International, and Quebecor World, and the acquisitions of Videotron by Quebecor, among many others. His expertise in leading corporations through significant transactions will be invaluable to Morphocell. Marc has been actively involved in board work, having served as chairman for Canada Post, NAV Canada, Aireon, and the Pembroke American Growth Fund, and a former director of Groupe TVA and Ovivo. His contributions to the community as the past chairman of the Montreal Children’s Foundation and a former director of the MUHC and the MUHC Foundation underscore his dedication and leadership. Our CEO, Massimiliano Paganelli, expressed his enthusiasm, saying, "Marc’s remarkable background and strategic insight align perfectly with our vision for growth and innovation." This key appointment demonstrates our commitment to robust governance and strategic refinement. Marc’s knowledge will support Morphocell in its growth to become a leading entity in the life sciences and biotechnology sectors in Quebec and Canada. Join us in welcoming Marc Courtois to the Morphocell Technologies family! #LifeSciences #Biotechnology #Innovation #Healthcare #Leadership #Growth https://lnkd.in/egER2G4C

Fondée en 2018, Morphocell Technologies a pour mission de transformer le traitement des maladies du foie. Grâce à la Stratégie québécoise en sciences de la vie et au financement reçu, l’entreprise demeure pionnière dans la recherche et le développement d’un traitement efficace pour les maladies hépatiques graves, le ReLiver. Le gouvernement du Québec soutient Morphocell Technologies par l’entremise du programme Impulsion PME, administré par Investissement Québec.   #santé #innovation #sciencesdelavie | Massimiliano Paganelli

We’re #hiring. Know anyone who might be interested? This is an amazing opportunity to join a diverse team of highly motivated scientists and engineers, as we develop life changing therapies built on cutting edge technologies! We look forward to hearing from you!

🌟 New board appointment at Morphocell Technologies! 🌟 We are delighted to welcome Didier Leconte to our Board of Directors as an independent member. Didier is a seasoned leader with an impressive track record in the life sciences and biotechnology sectors. With his extensive background, including significant roles at Fonds de solidarité FTQ and Investissement Québec, Didier has been instrumental in fostering innovation and supporting growth for many Canadian biotechs at various stages of development, with a widely recognized impact on the life sciences landscape across Canada. CEO Massimiliano Paganelli shares, "Didier's exceptional background and vision for innovation are perfectly aligned with our goals at Morphocell. His experience will be invaluable as we continue to push the boundaries of cell therapy and strengthen Quebec as a biotechnology hub." Didier himself is excited about his role, saying, "I am honored to join a pioneering company like Morphocell Technologies. I look forward to contributing to its mission of innovation and impacting healthcare on a global scale." This strategic addition to our board underscores Morphocell's commitment to enhancing our governance and propelling forward our vision of transforming patient care through groundbreaking therapies. Welcome aboard, Didier! 🎉 #Biotechnology #Leadership #HealthcareInnovation #CellTherapy #Quebec https://lnkd.in/eezb64un

We are proud to be part of the growing Quebec’s life sciences ecosystem #innovation #Québec #SQSV